BIOMARIN PHARMACEUTICAL INC - NOTE 0.599% 8/0 Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2017 to Q3 2024

Type / Class
Debt / NOTE 0.599% 8/0
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of BIOMARIN PHARMACEUTICAL INC - NOTE 0.599% 8/0 across Reporting Periods

Period Principal Value Change Price (% of par) (Median) Investors
2024 Q3 $0 $0 -$501,725,739 0
2024 Q2 $505,486,000 $502,268,011 +$56,282,568 99.43% 48
2024 Q1 $454,044,750 $446,464,227 +$12,893,132 98.38% 55
2023 Q4 $441,213,550 $437,405,199 +$38,612,654 98.59% 62
2023 Q3 $399,160,150 $392,611,057 -$20,178,643 97.1% 62
2023 Q2 $420,418,350 $414,229,225 -$16,303,106 98.37% 57
2023 Q1 $434,664,263 $451,530,202 +$32,816,110 102.6% 58
2022 Q4 $406,689,750 $432,619,074 -$25,305,769 106.32% 54
2022 Q3 $372,500,950 $370,134,821 -$5,258,285 99.33% 49
2022 Q2 $378,684,300 $375,132,226 -$6,308,447 99.01% 50
2022 Q1 $378,633,300 $378,218,157 +$23,476,834 100.0% 48
2021 Q4 $354,379,300 $370,772,018 -$45,882,457 104.67% 47
2021 Q3 $394,445,300 $405,334,466 -$3,414,739 102.53% 48
2021 Q2 $396,506,300 $413,180,185 -$70,368,448 103.84% 44
2021 Q1 $470,330,300 $481,428,452 +$19,396,517 101.88% 48
2020 Q4 $445,463,135 $478,977,819 +$16,292,881 107.27% 51
2020 Q3 $434,741,990 $456,373,728 +$2,093,914 104.9% 49
2020 Q2 $423,468,900 $523,473,501 +$5,040,694 122.32% 54
2020 Q1 $424,192,588 $444,431,842 +$57,268,058 104.64% 52
2019 Q4 $366,553,882 $388,746,400 -$116,441,443 105.72% 50
2019 Q3 $483,301,000 $476,814,970 -$7,278,171 98.54% 43
2019 Q2 $487,706,068 $508,853,510 +$21,852,590 103.81% 46
2019 Q1 $467,241,157 $480,261,000 -$21,755,310 102.32% 45
2018 Q4 $491,206,888 $489,940,000 +$16,032,312 99.44% 41
2018 Q3 $473,954,515 $503,868,213 +$63,249,280 106.52% 41
2018 Q2 $388,171,404 $395,200,546 +$22,297,025 101.27% 36
2018 Q1 $391,383,950 $370,028,817 -$27,110,848 94.07% 38
2017 Q4 $404,135,300 $404,330,916 +$2,267,998 99.87% 46
2017 Q3 $400,691,200 $406,783,596 +$406,783,596 101.5% 39